A powerful match - celebrating three years of Croda Pharma and Avanti
Working hand in hand, Avanti’s know-how and technology have proven to be highly complementary to our capability in drug delivery systems, vaccine adjuvants and immunotherapy.
Many staff joined the Croda family along with the Avanti acquisition, here are some of their stories:
Ethan CagleSafety Health and Environment Department
"After the acquisition, Croda invested heavily in the cGMP Manufacturing Facility essentially doubling the overall manufacturing space. This has lead to expansion of the process development group both in personnel and laboratory space, allowing us to increase development and optimization capacities. Our products are used in therapeutics from early phase clinical applications to commercial pharmaceuticals. It is extremely fulfilling to work on projects every day that have potential to improve the lives of so many people. Since the acquisition there has been significant investment in the future of Avanti products. From the initial transfer and scale-up of COVID vaccine raw materials to planned scale-ups of legacy products, the large-scale manufacturing capacities of other Croda sites around the world greatly expand the potential impact of Avanti technology".
Justin Martin, Lead Development Scientist in the cGMP Process Development Group